Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Urologic Diseases 1Nephritis 1Lymphoma, Non-Hodgkin 1Kidney Diseases 1Immune System Diseases 1Heart Failure 1Glomerulonephritis, IGA 1Glomerulonephritis 1Cardiomyopathies 1Autoimmune Diseases 1

Interventions

Cyclophosphamide 240Rituximab 187fludarabine phosphate 129Etoposide 110Peripheral Blood Stem Cell Transplantation 108Mycophenolic Acid 94Filgrastim 91Melphalan 90Whole-Body Irradiation 88fludarabine 80Busulfan 80Tacrolimus 71Cytarabine 66Cyclosporine 66Radiotherapy 62Methotrexate 53Antilymphocyte Serum 53Granulocyte Colony-Stimulating Factor 51Vincristine 49Carmustine 48Doxorubicin 41Prednisone 37Thiotepa 33Bendamustine Hydrochloride 32Bortezomib 30Methylprednisolone 29Dexamethasone 28Stem Cell Transplantation 27thymoglobulin 26ibritumomab tiuxetan 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, Non-Hodgkin × Valsartan × Clear all
NCT00162955 2012-05-08

Prevention of CHOP-induced Chronic Cardiotoxicity

Osaka City University

Phase 4 Completed
150 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Cardiomyopathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡